Agios Pharmaceuticals Inc (NASDAQ:AGIO) – Investment analysts at SunTrust Banks issued their Q3 2018 earnings per share estimates for shares of Agios Pharmaceuticals in a research note issued on Thursday. SunTrust Banks analyst Y. Suneja anticipates that the biopharmaceutical company will post earnings of ($1.67) per share for the quarter. SunTrust Banks currently has a “Buy” rating and a $101.00 target price on the stock. SunTrust Banks also issued estimates for Agios Pharmaceuticals’ Q4 2018 earnings at ($1.53) EPS, FY2018 earnings at ($6.48) EPS, FY2019 earnings at ($5.85) EPS, FY2020 earnings at ($5.40) EPS, FY2021 earnings at ($2.70) EPS and FY2022 earnings at ($0.60) EPS.
Other equities analysts have also issued reports about the stock. Canaccord Genuity set a $90.00 target price on shares of Agios Pharmaceuticals and gave the stock a “buy” rating in a research report on Tuesday, December 12th. Oppenheimer reiterated a “buy” rating and issued a $83.00 price objective on shares of Agios Pharmaceuticals in a research report on Monday, December 11th. Cann reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research report on Tuesday, December 5th. Zacks Investment Research upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating and set a $68.00 price objective on the stock in a research report on Tuesday, January 9th. Finally, BidaskClub upgraded shares of Agios Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday, January 16th. Four equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $85.50.
Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Wednesday, February 14th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.65) by ($0.16). The business had revenue of $9.80 million for the quarter, compared to analysts’ expectations of $12.65 million. Agios Pharmaceuticals had a negative return on equity of 76.67% and a negative net margin of 731.60%. The business’s revenue was down 56.7% on a year-over-year basis. During the same quarter last year, the business posted ($1.34) earnings per share.
Hedge funds and other institutional investors have recently modified their holdings of the business. Royal Bank of Canada boosted its position in shares of Agios Pharmaceuticals by 40.8% during the 2nd quarter. Royal Bank of Canada now owns 9,131 shares of the biopharmaceutical company’s stock worth $470,000 after purchasing an additional 2,648 shares in the last quarter. Ameriprise Financial Inc. boosted its position in shares of Agios Pharmaceuticals by 21.9% during the 2nd quarter. Ameriprise Financial Inc. now owns 49,994 shares of the biopharmaceutical company’s stock worth $2,572,000 after purchasing an additional 8,965 shares in the last quarter. Northern Trust Corp boosted its position in shares of Agios Pharmaceuticals by 31.3% during the 2nd quarter. Northern Trust Corp now owns 232,802 shares of the biopharmaceutical company’s stock worth $11,977,000 after purchasing an additional 55,560 shares in the last quarter. Alps Advisors Inc. boosted its position in shares of Agios Pharmaceuticals by 9.1% during the 3rd quarter. Alps Advisors Inc. now owns 47,473 shares of the biopharmaceutical company’s stock worth $3,169,000 after purchasing an additional 3,962 shares in the last quarter. Finally, Brown Advisory Inc. boosted its position in shares of Agios Pharmaceuticals by 8.5% during the 3rd quarter. Brown Advisory Inc. now owns 291,139 shares of the biopharmaceutical company’s stock worth $19,433,000 after purchasing an additional 22,736 shares in the last quarter. Institutional investors own 84.04% of the company’s stock.
In other news, major shareholder Corp /De/ Celgene acquired 851,154 shares of the stock in a transaction that occurred on Tuesday, January 23rd. The shares were purchased at an average cost of $67.00 per share, for a total transaction of $57,027,318.00. Following the transaction, the insider now directly owns 1,374,599 shares in the company, valued at approximately $92,098,133. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Scott Biller sold 2,146 shares of the business’s stock in a transaction on Friday, December 1st. The stock was sold at an average price of $60.79, for a total transaction of $130,455.34. Following the sale, the insider now owns 8,410 shares in the company, valued at $511,243.90. The disclosure for this sale can be found here. Over the last quarter, insiders sold 185,114 shares of company stock worth $14,021,325. 5.43% of the stock is currently owned by insiders.
About Agios Pharmaceuticals
Agios Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s therapeutic areas of focus are cancer and rare genetic metabolic disorders, which are a group of over 600 rare genetic diseases caused by mutations, or defects, of single metabolic genes. The Company’s cancer product candidates are enasidenib and ivosidenib (AG-120), which target mutated isocitrate dehydrogenase 2 (IDH2) and isocitrate dehydrogenase 1 (IDH1), respectively, and AG-881, which targets both mutated IDH1 and mutated IDH2.
Receive News & Ratings for Agios Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agios Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.